Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021254582 - EFFICACY OF (SOFOSBUVIR PLUS LEDIPASVIR) IN EGYPTIAN PATIENTS WITH COVID-19COMPARED TO STANDARD OF CARE TREATMENT.

Publication Number WO/2021/254582
Publication Date 23.12.2021
International Application No. PCT/EG2020/000013
International Filing Date 15.06.2020
IPC
A61K 31/439 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/7072 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
7072having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
CPC
A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/7072
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
7072having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • ALMAZA MILITARY FEVER HOSPITAL [EG]/[EG]
Inventors
  • EL-GOHARY, Mohamed Abdel-Salam
Priority Data
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) EFFICACY OF (SOFOSBUVIR PLUS LEDIPASVIR) IN EGYPTIAN PATIENTS WITH COVID-19COMPARED TO STANDARD OF CARE TREATMENT.
(FR) EFFICACITÉ DE (SOFOSBUVIR PLUS LÉDIPASVIR) CHEZ DES PATIENTS ÉGYPTIENS AYANT UNE AFFINITÉ ÉLEVÉE PAR RAPPORT À UNE NORME DE TRAITEMENT DE SOIN
Abstract
(EN) The antivirals ledipasvir is particularly attractive as therapeutics to combat the new corona virus with minimal side effects, commonly fatigue and headache. The drugs (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes. The present study aimed to test and suggest possible inhibitors, DAA drugs, currently in the market stop the infection immediately. Sofosbuvir, ledipasvir can be used against the new strain of coronavirus that emerged with promising results.
(FR) L'antiviral lédipasvir est particulièrement attractif en tant que thérapeutique pour lutter contre le nouveau coronavirus avec des effets secondaires minimaux, notamment la fatigue et les céphalées. Les médicaments (lédipasvir/sofosbuvir) pourraient être très efficaces grâce à leurs double action inhibitrice sur deux enzymes virales. La présente étude vise à tester et suggérer des inhibiteurs possibles, des médicaments DAA, actuellement sur le marché pour l'arrêt immédiat d'une infection. Le sofosbuvir, le lédipasvir peuvent être utilisés contre la nouvelle souche de coronavirus qui a émergé avec des résultats prometteurs.
Latest bibliographic data on file with the International Bureau